Silencing of voltage-gated potassium channel KV9.3 inhibits proliferation in human colon and lung carcinoma cells
Metrics: PDF 1787 views | HTML 2334 views | ?
Jeong-Ha Lee1, Jun-Won Park2, Jun Kyu Byun3, Hark Kyun Kim2, Pan Dong Ryu3, So Yeong Lee3 and Dae-Yong Kim1
1 Laboratory of Veterinary Pathology, Seoul National University, Seoul, Korea
2 Biomolecular Function Research Branch, National Cancer Center, Goyang, Gyeonggi, Korea
3 Veterinary Pharmacology, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, Korea
Dae-Yong Kim, email:
So Yeong Lee, email:
Keywords: cancer, colon, Kv9.3, lung, proliferation
Received: December 09, 2014 Accepted: February 03, 2015 Published: April 10, 2015
Voltage-gated potassium (Kv) channels are known to be involved in cancer development and cancer cell proliferation. KV9.3, an electronically silent subunit, forms heterotetramers with KV2.1 in excitable cells and modulates its electrophysiological properties. However, the role of KV9.3 alone in non-excitable cancer cells has not been studied. Here, we evaluated the effect of silencing KV9.3 on cancer cell proliferation in HCT15 colon carcinoma cells and A549 lung adenocarcinoma cells. We confirmed the expression of KV9.3 mRNA in HCT15 and A549 cells and showed that silencing KV9.3 using small interfering RNA caused G0/G1 cell cycle arrest and alterations in cell cycle regulatory proteins in both HCT15 and A549 cells without affecting apoptosis. Also, stable knockdown of KV9.3 expression using short-hairpin RNA inhibited tumor growth in SCID mouse xenograft model. Using a bioinformatics approach, we identified Sp1 binding sites in the promoter region of the gene encoding KV9.3. We further found that Sp1 bound to this region and showed that the Sp1 inhibitor, mithramycin A, induced a concentration-dependent decrease in KV9.3 expression. Taken together, these data suggest that knockdown of KV9.3 inhibits proliferation in colon carcinoma and lung adenocarcinoma cell lines and may be regulated by Sp1.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.